Cargando…

Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies

Novel immunotherapies continue to be developed and tested for application against a plethora of diseases. The clinical translation of immunotherapies requires an understanding of their mechanisms. The contributions of antibodies in driving long-term responses following immunotherapies continue to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Minott, Jessica A., van Vloten, Jacob P., Yates, Jacob G. E., Chan, Lily, Wood, Geoffrey A., Viloria-Petit, Alicia M., Karimi, Khalil, Petrik, James J., Wootton, Sarah K., Bridle, Byram W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708883/
https://www.ncbi.nlm.nih.gov/pubmed/36466867
http://dx.doi.org/10.3389/fimmu.2022.1038340
_version_ 1784841038257455104
author Minott, Jessica A.
van Vloten, Jacob P.
Yates, Jacob G. E.
Chan, Lily
Wood, Geoffrey A.
Viloria-Petit, Alicia M.
Karimi, Khalil
Petrik, James J.
Wootton, Sarah K.
Bridle, Byram W.
author_facet Minott, Jessica A.
van Vloten, Jacob P.
Yates, Jacob G. E.
Chan, Lily
Wood, Geoffrey A.
Viloria-Petit, Alicia M.
Karimi, Khalil
Petrik, James J.
Wootton, Sarah K.
Bridle, Byram W.
author_sort Minott, Jessica A.
collection PubMed
description Novel immunotherapies continue to be developed and tested for application against a plethora of diseases. The clinical translation of immunotherapies requires an understanding of their mechanisms. The contributions of antibodies in driving long-term responses following immunotherapies continue to be revealed given their diverse effector functions. Developing an in-depth understanding of the role of antibodies in treatment efficacy is required to optimize immunotherapies and improve the chance of successfully translating them into the clinic. However, analyses of antibody responses can be challenging in the context of antigen-agnostic immunotherapies, particularly in the context of cancers that lack pre-defined target antigens. As such, robust methods are needed to evaluate the capacity of a given immunotherapy to induce beneficial antibody responses, and to identify any therapy-limiting antibodies. We previously developed a comprehensive method for detecting antibody responses induced by antigen-agnostic immunotherapies for application in pre-clinical models of vaccinology and cancer therapy. Here, we extend this method to a high-throughput, flow cytometry-based assay able to identify and quantify isotype-specific virus- and tumor-associated antibody responses induced by immunotherapies using small sample volumes with rapid speed and high sensitivity. This method provides a valuable and flexible protocol for investigating antibody responses induced by immunotherapies, which researchers can use to expand their analyses and optimize their own treatment regimens.
format Online
Article
Text
id pubmed-9708883
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97088832022-12-01 Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies Minott, Jessica A. van Vloten, Jacob P. Yates, Jacob G. E. Chan, Lily Wood, Geoffrey A. Viloria-Petit, Alicia M. Karimi, Khalil Petrik, James J. Wootton, Sarah K. Bridle, Byram W. Front Immunol Immunology Novel immunotherapies continue to be developed and tested for application against a plethora of diseases. The clinical translation of immunotherapies requires an understanding of their mechanisms. The contributions of antibodies in driving long-term responses following immunotherapies continue to be revealed given their diverse effector functions. Developing an in-depth understanding of the role of antibodies in treatment efficacy is required to optimize immunotherapies and improve the chance of successfully translating them into the clinic. However, analyses of antibody responses can be challenging in the context of antigen-agnostic immunotherapies, particularly in the context of cancers that lack pre-defined target antigens. As such, robust methods are needed to evaluate the capacity of a given immunotherapy to induce beneficial antibody responses, and to identify any therapy-limiting antibodies. We previously developed a comprehensive method for detecting antibody responses induced by antigen-agnostic immunotherapies for application in pre-clinical models of vaccinology and cancer therapy. Here, we extend this method to a high-throughput, flow cytometry-based assay able to identify and quantify isotype-specific virus- and tumor-associated antibody responses induced by immunotherapies using small sample volumes with rapid speed and high sensitivity. This method provides a valuable and flexible protocol for investigating antibody responses induced by immunotherapies, which researchers can use to expand their analyses and optimize their own treatment regimens. Frontiers Media S.A. 2022-11-16 /pmc/articles/PMC9708883/ /pubmed/36466867 http://dx.doi.org/10.3389/fimmu.2022.1038340 Text en Copyright © 2022 Minott, van Vloten, Yates, Chan, Wood, Viloria-Petit, Karimi, Petrik, Wootton and Bridle https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Minott, Jessica A.
van Vloten, Jacob P.
Yates, Jacob G. E.
Chan, Lily
Wood, Geoffrey A.
Viloria-Petit, Alicia M.
Karimi, Khalil
Petrik, James J.
Wootton, Sarah K.
Bridle, Byram W.
Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies
title Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies
title_full Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies
title_fullStr Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies
title_full_unstemmed Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies
title_short Multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies
title_sort multiplex flow cytometry-based assay for quantifying tumor- and virus-associated antibodies induced by immunotherapies
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708883/
https://www.ncbi.nlm.nih.gov/pubmed/36466867
http://dx.doi.org/10.3389/fimmu.2022.1038340
work_keys_str_mv AT minottjessicaa multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies
AT vanvlotenjacobp multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies
AT yatesjacobge multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies
AT chanlily multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies
AT woodgeoffreya multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies
AT viloriapetitaliciam multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies
AT karimikhalil multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies
AT petrikjamesj multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies
AT woottonsarahk multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies
AT bridlebyramw multiplexflowcytometrybasedassayforquantifyingtumorandvirusassociatedantibodiesinducedbyimmunotherapies